Currently submitted to: Interactive Journal of Medical Research
Date Submitted: Jun 27, 2019
Open Peer Review Period: Jul 2, 2019 - Aug 27, 2019
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).
Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study
Hydroxychloroquine (HCQ) has been used to manage many inflammatory skin conditions. Nevertheless, retinopathy remains its most significant adverse effect. The American Academy of Ophthalmology (AAO) recommends baseline ophthalmologic screening in the first year of HCQ treatment. However, a recent study found an inadequate awareness of the recommendations. Furthermore, limited data are available regarding the implementation of the recommendations among dermatologists.
The purpose of this study was to assess dermatologists’ adherence to recommendations pertaining to their current practice regarding HCQ toxicity detection.
A self-administrated questionnaire was distributed between February 2, 2018, to May 4, 2018 among members of the Saudi Society of Dermatology. The questionnaire was designed by Shulman et al. Consisted of demographics-related questions and questions pertaining to each physician’s routine practice about the follow-up of HCQ-treated patients.
A total of 76 dermatologists completed the questionnaire. We achieved a response rate of 62.54%. More than half (43 [56.6%]) were male. Furthermore, more than half (41 [53.9%]) reported treating 1-3 patients with HCQ during the last year.Furthermore, two-thirds (47 [61.8%]) reported screening patients before initiating HCQ treatment. Regarding follow-up recommendations, 45 (59.2%) reported “yearly after starting treatment” for no-risk patients, while 72 (94.7%) reported “yearly within 5 years of treatment” for at-risk patients. Data were considered significant at P < 0.05. All analysis was performed by using SPSS, version 20 (IBM, Armonk, NY, USA).
Saudi dermatologists are not well informed about some aspects of the latest recommendations regarding screening for HCQ toxicity in terms of tests, follow-up timing, cessation of the drug, and causative agents. Therefore, we recommend conducting more studies in Saudi Arabia to determine the adherence of more physicians to the AAO recommendations. Furthermore, patient education regarding HCQ toxicity and increasing patient awareness is recommended for effective and safe HCQ use.
Request queued. Please wait while the file is being generated. It may take some time.
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.